Profile data is unavailable for this security.
About the company
PolyNovo Limited is an Australia-based medical technology company. The Company’s business includes designing, manufacturing and selling biomedical devices. Its principal activity is the development of medical devices for medical applications, utilizing the patented bioabsorbable polymer technology NovoSorb. NovoSorb is a family of proprietary medical grade polymers that can be utilized to manufacture medical devices designed to support tissue repair. NovoSorb polymer devices can be expressed in a variety of physical formats including foam, coatings, fibers, plastic structures, films, and biologic carriers. Its products include NovoSorb Biodegradable Temporizing Matrix (BTM) and NovoSorb MTX. NovoSorb BTM is a bilayer dermal matrix for the regeneration of the dermis when lost through extensive surgery, trauma or burn. NovoSorb MTX has applicability for single stage grafting in burns, chronic, and surgical wounds.
- Revenue in AUD (TTM)138.14m
- Net income in AUD9.88m
- Incorporated1998
- Employees301.00
- LocationPolynovo Ltd2/320 Lorimer StreetMELBOURNE 3207AustraliaAUS
- Phone+61 80095-8289
- Fax+61 38681-4099
- Websitehttps://polynovo.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jenscare Scientific Co Ltd | 2.76m | -50.33m | 631.63m | 174.00 | -- | 3.53 | -- | 228.82 | -0.685 | -0.685 | 0.0376 | 2.38 | 0.0125 | 0.0508 | -- | 72,580.27 | -23.35 | -- | -24.76 | -- | 88.09 | -- | -1,864.69 | -- | 6.39 | -854.86 | 0.0631 | -- | -- | -- | 52.25 | -- | -- | -- |
| Chemclin Diagnostics Co Ltd | 72.38m | 11.57m | 634.31m | 629.00 | 54.88 | 2.20 | -- | 8.76 | 0.1407 | 0.1407 | 0.8799 | 3.51 | 0.1957 | 1.06 | 16.07 | 561,724.90 | 3.13 | 9.46 | 3.44 | 10.57 | 66.36 | 73.98 | 15.99 | 30.72 | 6.62 | -- | 0.1472 | 44.55 | -2.03 | -0.8218 | -13.77 | -2.00 | 14.24 | -- |
| Polynovo Ltd | 138.14m | 9.88m | 645.94m | 301.00 | 65.38 | 7.77 | 50.87 | 4.68 | 0.0143 | 0.0143 | 0.1989 | 0.1204 | 1.17 | 0.901 | 6.10 | 458,946.80 | 8.37 | 2.17 | 10.38 | 2.71 | 91.53 | 94.89 | 7.15 | 2.10 | 2.51 | 3.21 | 0.1795 | 0.00 | 21.96 | 41.91 | 151.17 | -- | 9.45 | -- |
| Acotec Scientific Holdings Ltd | 121.89m | 20.75m | 648.49m | 645.00 | 30.41 | 2.18 | 20.53 | 5.32 | 0.3775 | 0.3775 | 2.24 | 5.25 | 0.3353 | 1.06 | 3.53 | 1,040,371.00 | 5.71 | 0.2467 | 6.45 | 0.289 | 75.23 | 81.33 | 17.02 | 0.7122 | 5.57 | -- | 0.1406 | 0.00 | 12.69 | 33.72 | 260.88 | 17.74 | 83.44 | -- |
| Goodwill E-Health Info Co Ltd | 91.37m | -79.54m | 651.60m | 1.87k | -- | 2.30 | -- | 7.13 | -2.82 | -2.82 | 3.24 | 10.04 | 0.1826 | 0.6860 | 0.5252 | 239,169.30 | -17.84 | -1.97 | -26.60 | -2.94 | 10.68 | 45.51 | -97.69 | -6.33 | 1.42 | -15.53 | 0.1827 | -- | -14.85 | 5.93 | -892.99 | -- | 94.81 | -- |
| Excelsior Medical Co Ltd | 392.47m | 35.92m | 657.13m | 774.00 | 17.07 | 1.54 | 11.19 | 1.67 | 4.58 | 4.58 | 49.99 | 50.57 | 0.4313 | 5.17 | 5.34 | -- | 4.87 | 5.04 | 10.24 | 9.61 | 21.52 | 20.55 | 11.30 | 10.94 | 1.41 | -- | 0.1465 | 81.48 | 3.71 | 5.75 | 3.30 | 8.42 | 18.34 | 5.92 |
| Allgens Medical Technology Co Ltd | 43.79m | -739.44k | 665.43m | 271.00 | -- | 2.26 | -- | 15.20 | -0.0374 | -0.0374 | 1.54 | 10.47 | 0.138 | 1.19 | 2.90 | 788,855.10 | -0.3699 | 5.24 | -0.3882 | 5.61 | 64.91 | 81.42 | -2.68 | 30.31 | 16.62 | -- | 0.029 | 6.47 | -9.03 | 4.09 | -123.35 | -- | -29.51 | -- |
| Kontour XiAn Medical Technology Co Ltd | 68.20m | 18.11m | 667.31m | 311.00 | 36.85 | 4.73 | -- | 9.79 | 1.09 | 1.09 | 4.10 | 8.47 | 0.4356 | 2.73 | 38.35 | 1,070,470.00 | 11.45 | 13.82 | 12.97 | 15.72 | 77.13 | 79.18 | 26.29 | 30.37 | 4.51 | 8.00 | 0.0595 | 28.58 | 17.06 | 16.85 | 17.07 | 11.22 | 37.93 | -- |
| Imricor Medical Systems Inc | 410.95k | -35.59m | 686.83m | -- | -- | 42.40 | -- | 1,671.30 | -0.1156 | -0.1156 | 0.0013 | 0.0505 | 0.0087 | 1.79 | 0.9973 | -- | -75.15 | -104.14 | -106.26 | -129.50 | -695.67 | -221.81 | -8,661.54 | -3,394.69 | 2.41 | -7.23 | 0.6846 | -- | -69.53 | -16.08 | 14.73 | -- | -10.16 | -- |
| Holder | Shares | % Held |
|---|---|---|
| FIL Investment Management (Australia) Ltd.as of 03 Apr 2025 | 37.53m | 5.43% |
| The Vanguard Group, Inc.as of 04 Feb 2026 | 22.96m | 3.32% |
| State Street Global Advisors, Australia, Ltd.as of 19 Sep 2025 | 22.68m | 3.28% |
| Vanguard Investments Australia Ltd.as of 31 Jan 2026 | 13.52m | 1.96% |
| FIL Investment Management (Hong Kong) Ltd.as of 03 Apr 2025 | 12.09m | 1.75% |
| BlackRock Fund Advisorsas of 06 Feb 2026 | 9.72m | 1.41% |
| Allianz Global Investors Asia Pacific Ltd.as of 31 Oct 2025 | 9.14m | 1.32% |
| Norges Bank Investment Managementas of 30 Jun 2025 | 8.33m | 1.21% |
| State Street Global Advisors Trust Co.as of 19 Sep 2025 | 4.84m | 0.70% |
| UBS Asset Management (Australia) Ltd.as of 27 Aug 2025 | 4.54m | 0.66% |
